EBS
Price
$9.67
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
8 days until earnings call
SUPN
Price
$34.16
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
6 days until earnings call
Ad is loading...

EBS vs SUPN

Header iconEBS vs SUPN Comparison
Open Charts EBS vs SUPNBanner chart's image
Emergent Biosolutions
Price$9.67
Change-$0.00 (-0.00%)
Volume$1.04M
CapitalizationN/A
Supernus Pharmaceuticals
Price$34.16
Change-$0.00 (-0.00%)
Volume$260.46K
CapitalizationN/A
View a ticker or compare two or three
EBS vs SUPN Comparison Chart
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
EBS vs. SUPN commentary
Oct 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Buy and SUPN is a StrongBuy.

COMPARISON
Comparison
Oct 30, 2024
Stock price -- (EBS: $9.67 vs. SUPN: $34.16)
Brand notoriety: EBS and SUPN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 52% vs. SUPN: 80%
Market capitalization -- EBS: $120.07M vs. SUPN: $1.84B
EBS [@Pharmaceuticals: Other] is valued at $120.07M. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.84B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileSUPN’s FA Score has 1 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • SUPN’s FA Score: 1 green, 4 red.
According to our system of comparison, both EBS and SUPN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 7 TA indicator(s) are bullish while SUPN’s TA Score has 6 bullish TA indicator(s).

  • EBS’s TA Score: 7 bullish, 3 bearish.
  • SUPN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, EBS is a better buy in the short-term than SUPN.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а -5.01% price change this week, while SUPN (@Pharmaceuticals: Other) price change was +1.46% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +8.21%. For the same industry, the average monthly price growth was +10.22%, and the average quarterly price growth was -2.43%.

Reported Earning Dates

EBS is expected to report earnings on Feb 20, 2025.

SUPN is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+8.21% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($1.84B) has a higher market cap than EBS($120M). SUPN has higher P/E ratio than EBS: SUPN (1677.00) vs EBS (17.73). EBS YTD gains are higher at: 302.917 vs. SUPN (18.037). SUPN has higher annual earnings (EBITDA): 90M vs. EBS (-518.2M). SUPN has more cash in the bank: 255M vs. EBS (112M). SUPN has less debt than EBS: SUPN (41.5M) vs EBS (860M). EBS has higher revenues than SUPN: EBS (1.02B) vs SUPN (608M).
EBSSUPNEBS / SUPN
Capitalization120M1.84B7%
EBITDA-518.2M90M-576%
Gain YTD302.91718.0371,679%
P/E Ratio17.731677.001%
Revenue1.02B608M168%
Total Cash112M255M44%
Total Debt860M41.5M2,072%
FUNDAMENTALS RATINGS
EBS vs SUPN: Fundamental Ratings
EBS
SUPN
OUTLOOK RATING
1..100
8017
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
10063
SMR RATING
1..100
9889
PRICE GROWTH RATING
1..100
3442
P/E GROWTH RATING
1..100
161
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (65) in the Biotechnology industry is in the same range as SUPN (95) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (63) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (100) in the Biotechnology industry. This means that SUPN’s stock grew somewhat faster than EBS’s over the last 12 months.

SUPN's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as EBS (98) in the Biotechnology industry. This means that SUPN’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (34) in the Biotechnology industry is in the same range as SUPN (42) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SUPN’s over the last 12 months.

SUPN's P/E Growth Rating (1) in the Pharmaceuticals Other industry is in the same range as EBS (16) in the Biotechnology industry. This means that SUPN’s stock grew similarly to EBS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSSUPN
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
Bullish Trend 2 days ago
72%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 20 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Ad is loading...
EBS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.732.16
+10.50%
GameStop Corp
BTC.X69907.7600001978.460900
+2.91%
Bitcoin cryptocurrency
AAPL233.401.99
+0.86%
Apple
SPY580.831.79
+0.31%
SPDR® S&P 500® ETF Trust
TSLA262.51-6.68
-2.48%
Tesla

EBS and

Correlation & Price change

A.I.dvisor tells us that EBS and AMRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EBS and AMRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+8.29%
AMRX - EBS
31%
Poorly correlated
+1.67%
ZOM - EBS
29%
Poorly correlated
+1.82%
ZTS - EBS
27%
Poorly correlated
+1.53%
SNDL - EBS
27%
Poorly correlated
+1.38%
ACET - EBS
27%
Poorly correlated
+2.14%
More

SUPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with PETQ. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then PETQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+0.68%
PETQ - SUPN
41%
Loosely correlated
N/A
AMPH - SUPN
34%
Loosely correlated
+2.23%
DVAX - SUPN
31%
Poorly correlated
+6.35%
AMRX - SUPN
29%
Poorly correlated
+1.67%
AQST - SUPN
28%
Poorly correlated
N/A
More